Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02940886 · ClinicalTrials.gov registry record · Phase 3
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)
A Phase 3 study, sponsored by Pharmacosmos A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,512
- Enrollment target
NCT02940886 is a Phase 3 study that has completed, run by Pharmacosmos A/S. The registered enrollment target is 1,512 participants.
The verdict
NCT02940886, a Phase 3 study, has completed, sponsored by Pharmacosmos A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,512 participants
- Enrollment target
Study Summary
Evaluate safety and efficacy of iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®) compared with iron sucrose (Venofer®), in subjects diagnosed with IDA.
Interventions
- DRUG Iron sucrose
- DRUG Iron isomaltoside/ferric derisomaltose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,512 participants |
| Start Date | 2016-11-08 |
| Est. Completion | 2018-03-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02940886
The ClinicalTrials.gov registry entry for NCT02940886 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,512 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacosmos A/S, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Iron sucrose is the first listed.
NCT02940886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02940886 about?
NCT02940886 is a clinical study titled "Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)". Evaluate safety and efficacy of iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®) compared with iron sucrose (Venofer®), in subjects diagnosed with IDA.
What is the current status of trial NCT02940886?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,512 participants. The study started on 2016-11-08. Estimated completion is 2018-03-28.
What interventions are being tested in trial NCT02940886?
The interventions under investigation include: Iron sucrose (DRUG), Iron isomaltoside/ferric derisomaltose (DRUG).
Who is sponsoring clinical trial NCT02940886?
This trial is sponsored by Pharmacosmos A/S, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.